The cancer chemopreventive synthetic retinoid N-(4-hydroxyphenyl)retinamide (HPR) can inhibit the growth and induce apoptosis of tumor cells. In this study we analysed the growth suppressive eect of HPR on human breast cancer cell lines in vitro and the role of the retinoblastoma protein (pRb) , target residues for cyclin-dependent kinase 2 (Cdk2) the former two, and Cdk4 the latter two. Interestingly, this dephosphorylation of pRb occurred in S-G2-M phase cells, as revealed by experiments on cells fractionated by FACS according to the cell cycle phase, hence suggesting that the retinoid interferes with the regulation of pRb phosphorylation. The in vitro phosphorylation of a GST-pRb recombinant substrate by Cdk2 immunocomplexes from MCF7, T47D and SKBR3 was markedly suppressed after HPR treatment, whereas that by Cdk4 complexes was suppressed in T47D and SKBR3 but not in MCF7. The steady-state levels of Cdk2, Cdk4 and Cyclin A proteins were unaected by HPR, while those of Cyclin D1 were signi®cantly reduced in all three cell lines. Interestingly, Cyclin D1 downregulation by HPR correlated with transcriptional repression, but not with enhanced proteolysis of Cyclin D1 typically elicited by other retinoids. Collectively, our data suggest that the antiproliferative activity of HPR arises from its capacity to maintain pRb in a de-phosphorylated growthsuppressive status in S-G2/M, possibly through Cyclin D1 downregulation and inhibition of pRb-targeting Cdks.
Introduction
HPR is a synthetic retinoic acid derivative with cancer chemopreventive and therapeutic activities in experimental systems (for review, see Moon et al., 1994; Formelli et al., 1996) . In animals, HPR signi®cantly inhibits the incidence of carcinogen-induced mammary and urinary bladder lesions, lymphoma induction in PIM transgenic mice (McCormick et al., 1996) , and causes complete regression of transplanted mammary, prostate and ovarian tumors (Pollard et al., 1991; Moon et al., 1994; Formelli et al., 1996) . A recently completed randomized clinical trial started in our Institute in 1987 to establish the ecacy of HPR for the prevention of controlateral breast cancer among women surgically treated for node-negative breast cancer, suggests a bene®cial eect in premenopausal women (Veronesi et al., 1999) .
In vitro, HPR suppresses the growth of several tumor cell lines, including breast, ovarian and small cell lung carcinomas (Bhatnager et al., 1991; Kalemkerian et al., 1995; Sabichi et al., 1998) , neuroblastomas (Mariotti et al., 1994) , leukemias and lymphomas (Delia et al., 1993) . In addition, HPR inhibits angiogenesis and endothelial cell motility (Pienta et al., 1996) , and triggers apoptotic cell death (Delia et al., 1993 (Delia et al., , 1995 Mariotti et al., 1994; Pienta et al., 1996) through caspase activation (Piedra®ta and Pfahl, 1997) .
In contrast to all trans retinoic acid and other derivatives, whose biological responses involve the nuclear receptors and transcriptional factors RARs and RXRs (Mangelsdorf et al., 1995) , HPR responses arise from both receptor-dependent and -independent eects (Lotan, 1995) . Accordingly, while apoptosis by HPR appears receptor-independent (Delia et al., 1993; Kitareewan et al., 1999) , and actually correlates with the ability of HPR to elicit intracellular free radicals and acidi®cation (Delia et al., 1997a; Angoli et al., 1996; Maurer et al., 1999; Suzuki et al., 1999) , transcriptional regulation of target genes (e.g. AP1) is retinoid-receptor dependent, according to data showing that HPR selectively activates the transcription by RAR-g, to a less extent by RAR-b, but not by RAR-a (Fanjul et al., 1996; Kazmi et al., 1996) .
Among the cell cycle-regulatory genes, c-myc transcription is markedly downregulated by HPR (Delia et al., 1995) , but whether this represents a direct eect of HPR on c-myc gene regulation, or an indirect consequence of reduced growth, remains undetermined. Recently, the tumor suppressor retinoblastoma protein pRb, a central regulator of the G1/S phase transition (Weinberg, 1995) , was found highly upregulated in HPR-treated breast cancer cells (Kazmi et al., 1996) , suggesting a link between the antiproliferative activity of the retinoid and pRb regulation. To further verify this issue, and to determine the role of G1 cyclin-dependent kinases (Cdks) that phosphorylate pRb, we examined the expression and activity of these proteins in HPR-treated human breast carcinoma cell lines.
Our results demonstrate that HPR not only induces dephosphorylation of pRb, but that this event occurs in S-G2/M phase cells. Additionally we demonstrate that HPR inhibits Cdk2 and Cdk4 kinase activities against pRb and downmodulates Cyclin D1 mRNA expression. Coupled together, these results suggest a model whereby the antiproliferative activity of HPR arises from its capacity to maintain pRb in a dephosphorylated and growth suppressive status through the inhibition of pRb-speci®c Cdks.
Results

Effect of HPR on proliferation and cell cycle progression
The growth response of human MCF7, T47D and SKBR3 breast cancer cells cultured for up to 48 h with 3 mM HPR, a clinically achievable concentration, was determined. Compared to untreated cells, cells treated with HPR showed an appreciable time-dependent growth suppression (Figure 1a ), amounting at 48 h to 25% in MCF7, 44% in T47D and 37% in SKBR3.
The eect of HPR on cell cycle progression was evaluated by DNA¯ow cyto¯uorimetric analysis after propidium iodide staining. Compared to exponentially growing cells, HPR-treated cells ( Figure 1b) showed a modest increase of G1 (*10 ± 13% at 24 h and *15 ± 20% at 48 h) and a concomitant decrease of S and G2/ M phase cells. However, no major block in a speci®c phase of the cell cycle was found.
Taken together, these results indicate that a pharmacological dose of HPR inhibits breast cancer cell growth unrelated to cell cycle phase-speci®c arrest.
pRb phosphorylation status after retinoid treatment
The retinoblastoma protein is a negative regulator of progression from G1 to S phase of the cell cycle (Weinberg, 1995; Planas-Silva and Weinberg, 1997) . This function of pRb, which rests on its ability to bind to and block the activity of E2F family of transcription factors and to recruit histone deacetylase (Harbour et al., 1999) , is ®nely modulated by phosphorylation of pRb which progressively release these interactions (Knudsen and Wang, 1997; Connell-Crowley et al., 1997; Harbour et al., 1999) . As the activity of certain compounds, including some retinoids, involves the pRb pathway (Brooks et al., 1996; Wilcken et al., 1996; Zhu et al., 1997; Chen et al., 1999) , we sought to determine the role of pRb in the response to HPR.
On immunoblots of exponentially growing breast cancer cells, hypophosphorylated (lower band) and hyperphosphorylated (upper band) pRb forms were both detected throughout the time-course of the experiment (Figure 2 , bottom panel). After 24 h of treatment with HPR, however, only the hypophosphorylated form of pRb remained (Figure 2 , upper and middle panels). Of note, the dephosphorylation of pRb in MCF7 was noted even when cells were grown in estrogen-free culture conditions. Moreover, alike HPR, RA led to phosphorylation changes, though less marked in MCF7 than in T47D or SKBR3 cells. The activity of pRb is dependent on the phosphorylation of its 16 potential cyclin-dependent kinase sites (for a review see Weinberg, 1995; Taya, 1997) , apparently achieved in a two-stage process by Cyclin D-Cdk4/6 and Cyclin E-Cdk2 complexes, which identify dierent consensus sequences for phosphorylation on pRb (Kitagawa et al., 1996; Adams et al., 1999) . To determine if pRb dephosphorylation by HPR occurred at speci®c residues, we analysed the phosphorylation of Cdk4 ( (Figure 3 ). However, following HPR treatment pRb-P-Ser 795 signal declined by 36 and 91% in MCF7, by 80 and 97% in T47D and by 27 and 50% in SKBR3 cells at 24 and 48 h, respectively. pRb-P-Thr 821 signal dropped rapidly in T47D (*95% at 24 h), more gradually in MCF7 (50% at 24 h and 96% at 48 h) and less markedly in SKBR3 (*50% at 48 h). pRb-P-Ser 780 signal decreased signi®cantly in MCF7 (by 90% at 24 h) and T47D (by 50% at 24 h and 90% at 48 h), and modestly in SKBR3, while pRb-P-Ser 612 appeared reduced by *70% in MCF7 and T47D at 48 h, and by 30% in SKBR3.
These results would thus indicate that most of the entire pool of pRb molecules undergoes dephosphorylation at Ser 
Regulation of pRb phosphorylation during cell cycle
Although the marked shift in pRb phosphorylation in cells exposed to HPR could arise as an indirect consequence of a G1 arrest, the modest accumulation of G1 phase cells that followed the treatment (see Figure 1b ) did not support this possibility. To investigate this issue more thoroughly, G1 and S-G2/ M fractions from T47D cells untreated or treated with HPR for 24 h were sorted by FACS (purity 496%) and analysed on Western blots with the phosphospeci®c pRb antibodies. It should be noticed that neither MCF7 nor SKBR3 could be used for such investigation because of the intrinsic diculty to obtain single cell suspensions from them. It can be seen (Figure 4 ) that G1 phase cells, whether or not treated with HPR, exhibited only dephosphorylated pRb. However, in contrast to S-G2/M cells from controls, which largely expressed hyperphosphorylated pRb, S-G2/M cells from treated samples mostly expressed underphosphorylated pRb. None of the phosphospeci®c pRb antibodies to Ser reacted with G1 phase fraction from untreated or HPR-treated cells (Figure 4) . Conversely, while S-G2/ M phase cells from controls strongly reacted with the phosphospeci®c antibodies, those from HPR-treated samples generated faint signals, concordant with a dephosphorylation of these pRb residues in HPRtreated S-G2/M cells.
Regulation of Cdks activity by HPR
To determine if the dephosphorylation of pRb was related to the inhibition of the pRb-speci®c kinases Cdk2 and Cdk4 (Knudsen and Wang, 1997; Connell- , Ser 612 and Thr 821 residues. Membranes were reprobed for b-actin, to normalize lanes for protein content Crowley et al., 1997; Zarkowska and Mittnacht, 1997; Lundberg and Weinberg, 1998) , these Cdks were immunoprecipitated from cells before and after HPR treatment and tested in kinases assays against a GSTpRb recombinant substrate. As shown in Figure 5 , considerable basal levels of Cdk2 activity towards GST-pRb were found in MCF7, T47D and SKBR3. However, following retinoid treatment, this activity was markedly inhibited, particularly in the former two cell lines. Cdk4 activity towards GST-pRb was detected in all three cell lines, but after HPR exposure it dropped by *70 and 50% in T47D and SKBR3, but not MCF7 cells. The decline in kinase activities could not be ascribed to diminished expression of Cdk2, Cdk4 or Cyclin A, since HPR had no eect on the levels of these proteins (Figure 6 ). Signi®cantly, however, Cyclin D1 protein levels markedly decreased in all three cell lines after retinoid treatment (Figure 6 ), a ®nding that may explain the drop in Cdk4 function given that its activity depends on Cyclin D1. Since RA and other retinoids induce proteasome-mediated Cyclin D1 degradation, and this may represent an eective growth suppressing and cancer chemoprevention signal (Langenfeld et al., 1997; Boyle et al., 1999) , we determined whether a similar mechanism accounted for the downregulation of Cyclin D1 by HPR. For this purpose, cells were pre-treated with a non-toxic dose of calpain inhibitor I (the inhibitor of the 26S proteasome pathway) prior to treatment with HPR. The results on T47D (Figure 7a ) demonstrated that the proteasome inhibitor was unable to prevent the downregulation of Cyclin D1 protein by HPR. As a similar ®nding was observed in MCF7 cells (data not shown), the involvement of the 26S proteasome in the regulation of Cyclin D1 by HPR appears thus unlikely. To determine whether HPR aected Cyclin D1 transcription, the steady-state levels of Cyclin D1 mRNA were analysed on Northern blots. The results evidenced a signi®cant decrease in Cyclin D1 mRNA starting 6 h after retinoid treatment in T47D (Figure 7b ) and MCF7 cells (not shown), thus indicating that Cyclin D1 protein is downregulated at transcriptional level by HPR.
Discussion
The retinoic acid derivative HPR demonstrates cancer chemopreventive and therapeutic properties in animal systems (Moon et al., 1994; Formelli et al., 1996) , and signi®cant activity in the prevention of controlateral breast cancer in women (Veronesi et al., 1999) . In vitro, HPR displays antiproliferative and apoptotic activities at doses achievable pharmacologically (Delia et al., Figure 4 Cell cycle phase-related phosphorylation of pRb. G1 and S-G2/M fractions (purity496%) were sorted by FACS from samples treated or not for 24 h with HPR and stained 30 min prior to harvesting with the¯uorochrome Hoechst 33342, as detailed in Materials and methods. Lysates from these fractions were Western blotted with antibodies to total or phosphospeci®c residues of pRb. Membranes were re-probed for b-actin, to normalize lanes for protein content. Hyper-and hypo-phosphorylated pRb are indicated by the upper and lower bars, respectively 1993; Mariotti et al., 1994; Pienta et al., 1996) . Alike other retinoids, HPR can activate the nuclear retinoic acid receptors, and in particular RAR-g and RAR-b, but not RAR-a (Fanjul et al., 1996; Kazmi et al., 1996) . However, HPR can elicit retinoid receptordependent and -independent responses (Delia et al., 1997a) , both potentially accounting for its biological and therapeutic activity. In order to elucidate the mechanisms underlying the antiproliferative activity of HPR, we investigated the retinoblastoma protein pRb, whose phosphorylation plays a key role in the G1/S transition phase (Weinberg, 1995; Louvet et al., 1996; Wilcken et al., 1996) , and whose continued hyperphosphorylation through S phase is required for the completion of DNA synthesis (Knudsen et al., 1998) . The study was also prompted by the evidence that certain retinoids exhibiting growth suppression modulate the phosphorylation and functional status of pRb (Brooks et al., 1996; Wilcken et al., 1996; Zhu et al., 1997) . In this study we have shown that treatment of breast cancer cells with HPR induced a marked dephosphorylation of pRb that involved the consensus residues for Cdk4 (Ser 780 and Ser
795
) and Cdk2 (Ser 621 and Thr
821
) relevant for the growth suppressive function of pRb (Connell-Crowley et al., 1997; Knudsen and Wang, 1997; Taya, 1997) . Our results, however, are in contrast with another study (Kazmi et al., 1996) showing a marked elevation of pRb levels, rather than phosphorylation changes, in HPRtreated MCF7 cells. The reason for this discrepancy is unclear, given that our data have been observed even under the same estrogen-free culture conditions indicated by these authors.
The level of pRb phosphorylation varies as function of cell cycle phase, most of the protein in G1 cells being underphosphorylated, and progressively hyperphosphorylated for cells in G1/S transition and G2/M phase (Weinberg, 1995) . In view of this, we undertook experiments to determine whether the dephosphorylation of pRb by HPR was the indirect consequence of an arrest in G1. Western analysis performed on cells fractionated according to the DNA content have allowed us to demonstrate expression of dephosphory- . These results, together with the¯ow cytometric data showing that HPR produces little cell cycle phase perturbations, strongly suggest that pRb dephosphorylation is not secondary to G1 arrest.
During the late G1 to S transition phase, a number of cyclin-dependent kinases including Cdk4-cyclin D, Cdk2-Cyclin E, Cdk2-Cyclin A phosphorylate pRb, possibly in a sequential manner and in at least 16 potential Ser/Thr-Pro consensus sites (Kitagawa et al., 1996; Zarkowska and Mittnacht, 1997; Lundberg and Weinberg, 1998) . To determine whether the dephosphorylation of pRb in HPR treated cells correlated with diminished Cdks activity, we analysed the capacity of Cdk2 and Cdk4 immunocomplexes to phosphorylate in vitro a pRb recombinant substrate. We have shown that Cdk2 activity, but not its expression, is markedly suppressed by HPR, particularly in MCF7 cells. Although the mechanism for this inhibition remains unclear, we would exclude the involvement of Cyclin A given that its levels do not change after treatment. Likewise, the activity of Cdk4 drops in SKBR3 and T47D but not in MCF7, while its expression is unaected by HPR treatment. Since the levels of the Cdk4-regulating protein Cyclin D1 decline in all cell lines, the drop in Cdk-4 activity may, at least in part, be explained by this event. Based on the fact that RA and other receptor-non-selective and growth-suppressive retinoids enhance proteasomedependent Cyclin D1 degradation, it has been hypothesized that proteolysis of this protein is a common chemoprevention signal, at least in normal and transformed human bronchial epithelial cells (Langenfeld et al., 1997; Boyle et al., 1999) . Although we cannot exclude that Cyclin D1 downregulation may equally represent a chemoprevention signal in response to HPR, nevertheless our results point out that unlike RA, HPR suppresses Cyclin D1 expression by a transcriptional rather than posttranslational mechanism, emphasizing further the dierent mode of action of these two retinoids.
As dephosphorylation of pRb can arise from druginduced activation of a pRb-speci®c phosphatase (Dou et al., 1995) , we have investigated this possibility by analysing protein extracts from control and HPR-treated MCF7 and T47D cells for their ability to dierentially dephosphorylate in vitro radiolabeled GST-pRb. Since no dierences have been found (D Delia, unpublished data), the role of a phosphatase in pRb dephosphorylation appears remote.
In conclusion, we have demonstrated that HPR causes accumulation of unphosphorylated pRb in S and G2/M phase cells, and this event correlates with suppression of the catalytic activity of pRb-targeting Cdks. The antiproliferative activity of HPR could thus reside in its capacity to inhibit the Cdk pathway (e.g. by downregulating Cyclin D1 expression) that sustains the phosphorylation of pre-existing (or de-novo synthesized) pRb necessary for the G1/S transition and S phase progression. Finally, these results emphasize the potential role of the pRb pathway in the chemopreventive and chemotherapeutic activity of HPR. Figure 7 Regulation of Cyclin D1 expression in T47D cells. In (a), the cells were pre-incubated or not with 100 mM calpain inhibitor I for 1.5 h prior to addition (or not) of HPR. Cells were harvested 10 h later, lysed and probed on Western blot for Cyclin D1. In (b), the RNA from untreated and HPR-treated cells was analysed by Northern blot with a Cyclin D1 cDNA probe
Materials and methods
Cell lines and treatments, flow cytometry and sorting
The breast cancer cell lines MCF7, T47D and SKBR3 were grown in RPMI-1640 (Bio-Whittaker, Walkersville, MD, USA) plus 10% heat-inactivated fetal calf serum (FCS) (Irvine Scienti®c, Santa Ana, CA, USA), 100 u/ml penicillin, 100 mg/ml streptomycin, and 2 mmol/l glutamine. In speci®ed cases, cells were grown in estrogen-free conditions using phenol red-free RPMI-1640 (Sigma, St. Louis, MO, USA) and 10% charcoal-stripped FCS (Sigma). HPR was a gift of RW Johnson Pharmaceutical Research Institute, Spring House, PA, USA, and all-trans retinoic acid (RA) was from Sigma. Ten-mM stock solutions of HPR in ethanol and RA in DMSO, stored at 7208C, were diluted 1 : 10 in FCS prior to further dilutions. Cell suspensions from adherent cultures were obtained by incubation with Trypsin-Versene (BioWhittaker), and viable cells counted on a hemocytometer after trypan blue staining. The calpain inhibitor I (Calbiochem, CA, USA) was used as described (Langenfeld et al., 1997) . Brie¯y, cells were pre-treated for 1.5 h with non-toxic doses of calpain inhibitor I (100 mg for T47D and 25 mg for MCF7) before addition or not of 3 mM HPR, and after 12 h were harvested and used for Western analysis. DNA¯ow cytometric determinations were performed as described (Delia et al., 1995) on cell suspensions treated for 20 min with 1 mg/ ml RNase (Sigma) and 0.5% saponin in PBS, stained with 25 mg/ml propidium iodide and analysed on a FACSVantage instrument (Becton-Dickinson, San JoseÂ , CA, USA). For cell sorting, untreated or retinoid-treated samples were incubated for 20 min at 378C with 10 mg/ml of the DNA-speci®c uorochrome Hoechst 33342 (Calbiochem, La Jolla, CA, USA), then trypsinized and separated according to DNA content with the FACSVantage instrument ®tted with an argon ion laser (20 mW of UV output light) and with a refrigeration system to keep samples cool while sorting (Delia et al., 1997b) .
Gel electrophoresis, immunoblots, densitometric analysis
Western blots were performed as described (Delia et al., 1997b) . Brie¯y, cells were lysed in 0.125 M Tris-HCl, pH 6.8, 5% SDS, 1 mM PMSF, 10 mg/ml pepstatin, 100 KIU/ml aprotinin, 10 mg/ml leupeptin (all from Calbiochem) and 1 mM sodium orthovanadate (Sigma). After boiling for 2 min, sonication for 20 s and protein quantitation by the micro-BCA method (Pierce, Rockford, IL, USA), lysates were loaded (30 mg of protein plus 5% b-mercaptoethanol) on 7 or 12% SDS ± PAGE, size-fractionated and electroblotted onto PVDF membranes (Millipore, Bedford, MA, USA). After blocking with 5% non-fat milk in PBS plus 0.1% Tween (Sigma), the membranes were incubated overnight with appropriate dilutions (1 : 800 to 1 : 1500) of primary antibody, washed, incubated for 1 h with peroxidase-labeled secondary antibody (1 : 2000), washed again and revealed by enhanced chemiluminescence (ECL) (Amersham, Amersham, UK). Monoclonal antibodies were employed to detect human p53 (clone DO7, Dako), pRb (Cat. 14001A, Pharmingen), Cyclin A (Clone 6E6, Novocastra Laboratories, UK) and Cyclin D1 (Clone DCS6, Neomarkers, Freemont, CA, USA), and rabbit antibodies for phosphorylated pRb at Ser 612 , Ser 780 and Thr 821 (Kitagawa et al., 1996; Adams et al., 1999) , and Ser 795 (Cat: 9301S, New England Biolabs, Beverly, MA, USA). Blots were reprobed with a rabbit antibody to bactin (Sigma) for protein content normalization. Bands on ®lms were optically scanned (DuoScan, Agfa, Germany) and quantitated by ImageQuant software analysis (Molecular Dynamics).
Kinase assays
Cdk2 activity was determined according to Gorospe et al. (1996) on cell pellets lysed in 50 mM Tris-HCL, pH 7.5 plus 250 mM NaCl, 0.1% Triton X-100, 5 mg/ml pepstatin, 10 mg aprotinin, 1 mM NaF, 0.1 mM PMSF 0.1 mM Na vanadate, 1 mM EDTA. After syringing through a 25-gauge needle and 15 min incubation on ice, lysates were centrifuged, quanti®ed and pre-cleared for 2 h at 48C with Protein A-Sepharose beads (Pharmacia, Norway) plus normal rabbit serum (Dako, Norway). After centrifugation, lysates were split into two aliquots, one incubated with 20 mg of the anti-cdk2 monoclonal antibody (Transduction Laboratories, Lexington, KY, USA), the other with a mouse control antibody. After 3 h, the immunocomplexes were recovered with an antimouse antibody bound to Protein A-Sepharose. The beads were then washed four times each in lysis and kinase buer (50 mM Tris HCL, pH 7.4, 10 mM MgCl 2 , 1 mM DTT), resuspended in 20 ml kinase buer plus 20 mM ATP, 2 mM EGTA, 10 mCi[g-32 P]ATP and 5 mg of GST-pRb (763-928) fusion protein puri®ed from BL21pLYS bacteria expressing pGEX-pRb(763-928) (Zarkowska and Mittnacht, 1997) , kindly provided by Dr S Mittnacht. After 30 min at 308C, reactions were stopped with Laemmli buer. For Cdk4 assays (Matsushime et al., 1994) cells were lysed in 50 mM HEPES pH 7.5, 150 mM NaCl, 2.5 mM EGTA, 1 mM EDTA, 0.1% Tween-20, 10% glycerol, 0.1% PMSF, 5 mg/ml pepstatin, 10 mg/ml aprotinin, 1 mM NaF, 0.1 mM Na vanadate. After preclearing as above, and incubation with 20 mg of a monoclonal antibody to Cdk4 (Transduction Laboratories), or with a mouse control antibody, immunocomplexes were recovered with an anti-mouse antibody bound to Protein ASepharose, washed four times each with lysate buer and kinase buer (50 mM HEPES, pH 7.5, 10 mM MgCl 2 , 1 mM DTT), and incubated for 30 min at 308C in 20 ml of kinase buer plus 0.1 mM Na vanadate, 1 mM NaF, 20 mM ATP, 10 mCi[g-32 P]ATP, 0.45 mg GST-Rb. The samples were resolved on 12% SDS ± PAGE. After overnight exposure to autoradiographic ®lms, gels were electroblotted onto PVDF membranes and tested for Cdk2 and Cdk4 by ECL.
Northern blots
Total RNA was extracted from untreated and HPR-treated cells by RNAzol (Biotex, Houston, TX, USA), size fractionated (10 mg/lane) on agarose gels and blotted onto membranes which, after UV crosslinking, were hybridized as reported (Delia et al., 1997b) to a human Cyclin D1 cDNA probe radiolabeled by multiprime labeling kit (Amersham, UK) to a speci®c activity of 1 ± 2610 9 c.p.m./mg with [ 32 P]. Binding of the probe was detected by autoradiography.
